|
| 36370742 | Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. | Lancet Haematol | 2023 |
| 37690903 | Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results. | Clin Lymphoma Myeloma Leuk | 2023 |
| 37675796 | Ethno-demographic disparities in humoral responses to the COVID-19 vaccine among healthcare workers. | J Med Virol | 2023 |
| 37422688 | A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. | J Hematol Oncol | 2023 |
| 37116523 | Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2023 |
| 36724515 | Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. | Blood Adv | 2023 |
| 36547666 | Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia. | Clin Cancer Res | 2023 |
| 36845850 | Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia. | Ther Adv Hematol | 2023 |
| 36795308 | Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors. | Curr Cardiol Rep | 2023 |
| 34491344 | Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. | J Natl Cancer Inst | 2022 |
| 35511672 | Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. | Haematologica | 2022 |
| 35767897 | International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. | Blood | 2022 |
| 35643868 | Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. | Leukemia | 2022 |
| 35570071 | Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. | Blood Rev | 2022 |
| 35818053 | A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. | J Hematol Oncol | 2022 |
| 35455624 | Implementing Rounding Checklists in a Pediatric Oncologic Intensive Care Unit. | Children (Basel) | 2022 |
| 35357036 | Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. | Am J Hematol | 2022 |
| 36524980 | Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. | Future Oncol | 2022 |
| 36037624 | Long-term results of the treatment of adolescents and adults with acute lymphoblastic leukemia with a pediatric-inspired regimen delivered on an outpatient basis: A single institution experience. | Leuk Res | 2022 |
| 36289532 | Efficacy and safety of CPX-351 versus 7â¿¿+â¿¿3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial. | J Hematol Oncol | 2022 |
| 36054756 | Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. | Am J Hematol | 2022 |
| 35317837 | Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. | J Hematol Oncol | 2022 |
| 35235189 | Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis. | Int J Hematol | 2022 |
| 34991679 | Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. | J Hematol Oncol | 2022 |
| 32561839 | The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. | Leukemia | 2021 |
| 33853292 | A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. | Haematologica | 2021 |
| 33851349 | Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. | Int J Hematol | 2021 |
| 33740113 | Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. | Ann Hematol | 2021 |
| 33681815 | Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. | Blood Cancer Discov | 2021 |
| 33597098 | Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. | Clin Lymphoma Myeloma Leuk | 2021 |
| 33823073 | Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. | Cancer | 2021 |
| 33736651 | Third-line therapy for chronic myeloid leukemia: current status and future directions. | J Hematol Oncol | 2021 |
| 33787984 | High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells. | Ann Hematol | 2021 |
| 33618754 | Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. | J Hematol Oncol | 2021 |
| 33731681 | Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. | Blood Cancer J | 2021 |
| 33638218 | Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy. | Eur J Haematol | 2021 |
| 33614514 | Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. | Front Oncol | 2021 |
| 33724305 | Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. | Blood Adv | 2021 |
| 34970488 | Retrospective Review of Flexible Bronchoscopy in Pediatric Cancer Patients. | Front Oncol | 2021 |
| 34673442 | Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosomeâ¿¿positive leukemias. | Leuk Res | 2021 |
| 34438444 | Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel. | Blood Adv | 2021 |
| 34407542 | A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. | Blood | 2021 |
| 34407543 | Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. | Blood | 2021 |
| 34425075 | Chronic myeloid leukaemia. | Lancet | 2021 |
| 34424319 | Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. | Blood Adv | 2021 |
| 34130720 | Impact of frontline treatment approach on outcomes of myeloid blast phase CML. | J Hematol Oncol | 2021 |
| 33991360 | Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. | Am J Hematol | 2021 |
| 33989269 | Asciminib for the treatment of patients with chronic myeloid leukemia. | Clin Adv Hematol Oncol | 2021 |
| 34125316 | Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. | Curr Oncol Rep | 2021 |
| 34342734 | The Care of the Leukemic Patients in Times of SARS-CoV-2. | Curr Oncol Rep | 2021 |